{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:28:19Z","timestamp":1761870499430,"version":"build-2065373602"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.3816\/clml.2010.n.001","type":"journal-article","created":{"date-parts":[[2010,2,8]],"date-time":"2010-02-08T21:01:27Z","timestamp":1265662887000},"page":"11-20","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["The 51st Annual Meeting of the American Society of Hematology"],"prefix":"10.3816","volume":"10","author":[{"given":"Sonia","family":"Cunningham","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabeeha","family":"Muneer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aarati","family":"Ranganathan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marissa","family":"Shrader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James R.","family":"Berenson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce","family":"Cheson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge E.","family":"Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CLML.2010.n.001_bib1","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1200\/JCO.2005.09.131","article-title":"Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte","volume":"23","author":"Feugier","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.001_bib2","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomized controlled trial by the MabThera International Trial (MInT) Group","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.3816\/CLML.2010.n.001_bib3","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","article-title":"Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma","volume":"24","author":"Habermann","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.001_bib4","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1182\/blood-2003-06-2095","article-title":"Twoweekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL","volume":"104","author":"Pfreundschuh","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.001_bib5","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","article-title":"Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)","volume":"9","author":"Pfreundschuh","year":"2008","journal-title":"Lancet Oncol"},{"issue":"suppl","key":"10.3816\/CLML.2010.n.001_bib6","first-page":"435s","article-title":"A phase III trial comparing R-CHOP 14 and R-CHOP 21 for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin's lymphoma","volume":"27","author":"Cunningham","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.001_bib7","doi-asserted-by":"crossref","unstructured":"Delarue R, Tilly H, Salles G, et al. R-CHOP14 Compared to R-CHOP21 in elderly patients with diffuse large B-cell lymphoma: results of the interim analysis of the LNH03-6B GELA Study. Paper presented at: the Annual Meeting of the American Society of Hematology; December 5-8, 2009; New Orleans, LA. Abstract 406.","DOI":"10.1182\/blood.V114.22.406.406"},{"key":"10.3816\/CLML.2010.n.001_bib8","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1200\/JCO.2008.18.7252","article-title":"Bendamustine: rebirth of an old drug","volume":"27","author":"Cheson","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.001_bib9","article-title":"In vitro and ex vivo activity of SDX-105 (bendamustine) in drug-resistant lymphoma cells","volume":"45","author":"Leoni","year":"2004","journal-title":"Am Assoc Cancer Res"},{"key":"10.3816\/CLML.2010.n.001_bib10","first-page":"45","article-title":"SDX-105 (bendamustine) inhibits growth of SU-DHL-1 and Daudi lymphoma xenografts in SCID mice","author":"Kanekal","year":"2004","journal-title":"Am Assoc Cancer Res"},{"key":"10.3816\/CLML.2010.n.001_bib11","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","article-title":"Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma","volume":"23","author":"Rummel","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.001_bib12","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2008.17.0001","article-title":"Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma","volume":"26","author":"Robinson","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.001_bib13","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1182\/blood.V114.22.405.405","volume":"114","author":"Rummel","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.001_bib14","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/MOH.0b013e32832b89a9","article-title":"The spectrum of peripheral T-cell lymphomas","volume":"16","author":"O'Leary","year":"2009","journal-title":"Curr Opin Hematol"},{"key":"10.3816\/CLML.2010.n.001_bib15","first-page":"508","article-title":"Pralatrexate, a dihydrofolate reductase inhibitor for the potential treatment of several malignancies","volume":"11","author":"Molina","year":"2008","journal-title":"IDrugs"},{"key":"10.3816\/CLML.2010.n.001_bib16","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.1200\/JCO.2008.20.8470","article-title":"Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies","volume":"27","author":"O'Connor","year":"2009","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"10.3816\/CLML.2010.n.001_bib17","first-page":"449s","article-title":"PROPEL: Results of the pivotal, multicenter, phase II study of pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL)","volume":"27","author":"O'Connor","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.001_bib18","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1182\/blood.V114.22.1681.1681","article-title":"Correlation Between Baseline Methylmalonic Acid Status and Mucositis Severity in the PROPEL Study: Implications for Vitamin Prophylaxis","volume":"114","author":"Pro","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.001_bib19","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1182\/blood.V114.22.1675.1675","article-title":"Safety and Management of Pralatrexate Treatment in Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)","volume":"114","author":"Pinter-Brown","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.001_bib20","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1182\/blood.V114.22.1678.1678","article-title":"Pralatrexate Induces Responses in Patients with Highly Refractory Peripheral T-Cell Lymphoma (PTCL)","volume":"114","author":"Savage","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.001_bib21","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1182\/blood.V114.22.1126.1126","article-title":"International Randomized Study of Interferon Vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib","volume":"114","author":"Deininger","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.001_bib22","first-page":"114","article-title":"Nilotinib demonstrates superior efficacy compared withimatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase: results from the international randomized phase III ENESTnd trial","author":"Saglio","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.001_bib23","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/S0140-6736(09)60221-X","article-title":"Multiple myeloma","volume":"374","author":"Raab","year":"2009","journal-title":"Lancet"},{"key":"10.3816\/CLML.2010.n.001_bib24","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1182\/blood.V114.22.3859.3859","article-title":"Bortezomib plus melphalan-prednisone continues to demonstrate a survival benefit Vs elphalanprednisone in the phase III VISTA trial in previously untreated multiple myeloma after 3 years' follow-up and extensive subsequent therapy use","volume":"114","author":"Mateos","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.001_bib25","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1200\/JCO.2008.18.8573","article-title":"Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure","volume":"27","author":"Spencer","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.001_bib26","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1200\/JCO.2009.24.0150","article-title":"Thalidomide maintenance in multiple myeloma: certainties and controversies","volume":"27","author":"Cavo","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.001_bib27","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1182\/blood.V99.9.3163","article-title":"Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients","volume":"99","author":"Berenson","year":"2002","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.001_bib28","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood.V114.22.3.3","volume":"114","author":"Mateos","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.001_bib29","first-page":"99","article-title":"Front line treatment of elderly multiple myeloma in the era of novel agents","volume":"3","author":"Venon","year":"2009","journal-title":"Biologics"},{"key":"10.3816\/CLML.2010.n.001_bib30","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N Engl J Med"},{"key":"10.3816\/CLML.2010.n.001_bib31","doi-asserted-by":"crossref","unstructured":"Mateos M-V, Richardson P, Schlag R, et al. Bortezomib plus melphalan\u2013prednisone continues to demonstrate a survival benefit vs melphalan\u2013prednisone in the phase III VISTA trial in previously untreated multiple myeloma after 3 years' follow-up and extensive subsequent therapy use. Presented at: the 51st Annual Meeting of the American Society of Hematology; December 5-8, 2010; New Orleans, LA. Abstract 3859.","DOI":"10.1182\/blood.V114.22.3859.3859"},{"key":"10.3816\/CLML.2010.n.001_bib32","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1182\/blood-2006-08-042275","article-title":"Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma","volume":"109","author":"Palumbo","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.001_bib33","unstructured":"Palumbo A, Bringhen S, Rossi D, et al. Bortezomib, melphalan, prednisone and thalidomide (VMPT) followed by maintenance with bortezomib and thalidomide for initial treatment of elderly multiple myeloma patients. Presented at: the 51st Annual Meeting of the American Society of Hematology; December 5-8, 2010; New Orleans, LA. Abstract 128."}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011700805?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011700805?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:23:23Z","timestamp":1761870203000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265011700805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["S2152265011700805"],"URL":"https:\/\/doi.org\/10.3816\/clml.2010.n.001","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2010,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The 51st Annual Meeting of the American Society of Hematology","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CLML.2010.n.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}